The threat of coronavirus is not over yet. The only way to avoid it is vaccination. Recently, 'Indian Immunologicals Limited' (IIL) announced on Tuesday that it has developed an intranasal (nasal) vaccine against COVID-19. This new drug has been developed in collaboration with Griffith University in Australia, and this vaccine can be taken through the nose without a needle.
IIL Managing Director K Anand Kumar described this achievement as an important step in the fight against COVID-19. He said in a statement, that through this vaccine, we want to increase vaccination rates and protect as many people as possible.
New vaccine, new hope
This new intranasal vaccine is a new technology against COVID-19. In the process of its development, Griffith University and IIL have jointly developed a nasal drug that can be given directly through the nose without the need for a needle. This vaccine can be especially beneficial for those who are afraid of needles or who have difficulty with routine vaccination.
Benefits and challenges of vaccination
According to IIL, the number of cases and deaths related to COVID-19 is still a matter of concern. According to the company's statement, about 1,700 people are dying every week due to COVID-19 worldwide. Thus, the need for a new and convenient vaccination method becomes even more important.
The intranasal vaccine will not only simplify the vaccination process but can also increase vaccination rates. With this new method of vaccination, people will get more ease and convenience for vaccination, which will help in the fight against the epidemic.
(PC: Freepik)
